Literature DB >> 26241666

Did NICE guidelines and the Quality Outcomes Framework change GP antidepressant prescribing in England? Observational study with time trend analyses 2003-2013.

Tony Kendrick1, Beth Stuart2, Colin Newell2, Adam W A Geraghty2, Michael Moore2.   

Abstract

BACKGROUND: Both the 2004 NICE depression guidelines and 2006 general practice Quality Outcomes Framework (QOF) encouraged improved targeting of antidepressant treatment for depression.
METHODS: Possible effects of the NICE guideline from January 2005, and QOF from April 2006, on rates of GP antidepressant prescribing were examined using time trend analyses of anonymised data from 142 English practices contributing to the Clinical Practice Research Datalink (CPRD), 2003-2013.
RESULTS: Sustained reductions were found in the proportion of first-ever depression episodes treated within 12 months, of 4.2% (95% C.I. 1.0-7.3%) following introduction of the NICE guideline, and 4.4% (2.3-6.5%) following introduction of the QOF. Treatment rates for first-ever episodes fell from 72.5% (70.8-74.1%) in Quarter 2 (Q2) 2003 to 61.0% (59.3-62.7%) in Q1 2012, but treatment rates for recurrent episodes increased from 74.3% (72.8-75.8%) to 77.8% (76.5-79.1%), so overall rates remained around 70%. Mean prescriptions per patient per year doubled from 2.06 (2.05-2.07) to 3.98 (3.97-3.99). LIMITATIONS: Participating practices were larger than average and not representative across regions. Inferences of cause and effect from time trend analyses are subject to the possibility of unidentified confounders. No data were available on depression severity or appropriateness of prescribing.
CONCLUSIONS: Rates of GP antidepressant treatment for patients with incident depression fell following introduction of NICE depression guidelines and the QOF, but treatment rates for recurrent depression increased. Prescription numbers increased due to longer treatment courses. To impact on antidepressant prescribing rates, guidelines and performance indicators must address recurrent and long-term prescribing, rather than initial treatment decisions.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressants; Depression; Guidelines; Pay for performance; Primary care; QOF

Mesh:

Substances:

Year:  2015        PMID: 26241666     DOI: 10.1016/j.jad.2015.06.052

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  18 in total

Review 1.  Green fingers and clear minds: prescribing 'care farming' for mental illness.

Authors:  Helen Elsey; Jenni Murray; Rachel Bragg
Journal:  Br J Gen Pract       Date:  2016-02       Impact factor: 5.386

2.  Characterizing treatment pathways at scale using the OHDSI network.

Authors:  George Hripcsak; Patrick B Ryan; Jon D Duke; Nigam H Shah; Rae Woong Park; Vojtech Huser; Marc A Suchard; Martijn J Schuemie; Frank J DeFalco; Adler Perotte; Juan M Banda; Christian G Reich; Lisa M Schilling; Michael E Matheny; Daniella Meeker; Nicole Pratt; David Madigan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

3.  Managing Antidepressant Discontinuation: A Systematic Review.

Authors:  Emma Maund; Beth Stuart; Michael Moore; Christopher Dowrick; Adam W A Geraghty; Sarah Dawson; Tony Kendrick
Journal:  Ann Fam Med       Date:  2019-01       Impact factor: 5.166

4.  Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.

Authors:  A John; A L Marchant; D L Fone; J I McGregor; M S Dennis; J O A Tan; K Lloyd
Journal:  Psychol Med       Date:  2016-12       Impact factor: 7.723

5.  'You feel like your whole world is caving in': A qualitative study of primary care patients' conceptualisations of emotional distress.

Authors:  Adam Wa Geraghty; Miriam Santer; Samantha Williams; Jennifer Mc Sharry; Paul Little; Ricardo F Muñoz; Tony Kendrick; Michael Moore
Journal:  Health (London)       Date:  2016-10-01

6.  Influences on antidepressant prescribing trends in the UK: 1995-2011.

Authors:  Becky Mars; Jon Heron; David Kessler; Neil M Davies; Richard M Martin; Kyla H Thomas; David Gunnell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-11-24       Impact factor: 4.328

7.  A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.

Authors:  George Salaminios; Larisa Duffy; Anthony Ades; Ricardo Araya; Katherine S Button; Rachel Churchill; Tim Croudace; Catherine Derrick; Padraig Dixon; Christopher Dowrick; Simon Gilbody; William Hollingworth; Vivien Jones; Tony Kendrick; David Kessler; Daphne Kounali; Paul Lanham; Alice Malpass; Tim J Peters; Derek Riozzie; Jude Robinson; Debbie Sharp; Laura Thomas; Nicky J Welton; Nicola Wiles; Glyn Lewis
Journal:  Trials       Date:  2017-10-24       Impact factor: 2.279

8.  Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology.

Authors:  Clément François; Adrian Tanasescu; François-Xavier Lamy; Nicolas Despiegel; Bruno Falissard; Ylana Chalem; Christophe Lançon; Pierre-Michel Llorca; Delphine Saragoussi; Patrice Verpillat; Alan G Wade; Djamel A Zighed
Journal:  J Mark Access Health Policy       Date:  2017-09-13

9.  Does depression diagnosis and antidepressant prescribing vary by location? Analysis of ethnic density associations using a large primary-care dataset.

Authors:  P Schofield; J Das-Munshi; R Mathur; P Congdon; S Hull
Journal:  Psychol Med       Date:  2016-02-16       Impact factor: 7.723

Review 10.  Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments.

Authors:  Niklas Bobrovitz; Carl Heneghan; Igho Onakpoya; Benjamin Fletcher; Dylan Collins; Alice Tompson; Joseph Lee; David Nunan; Rebecca Fisher; Brittney Scott; Jack O'Sullivan; Oliver Van Hecke; Brian D Nicholson; Sarah Stevens; Nia Roberts; Kamal R Mahtani
Journal:  BMC Med       Date:  2018-07-26       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.